Health Care Equipment

Chunli Medical

Spring International to Hold AGM on May 26 to Consider Repurchasing up to 10% of H Shares

Spring Care Medical reports a 6.27% increase in Q1 net profit, despite a 5.6% drop in revenue, with improved operating cash flow

SpringMed Publishes 2025 Annual Report, Emphasizing Sales Growth and R&D Directions

Chunli Medical released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 216.97 M, actual EPS CNY 0.16

Chunli Medical to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Spring Medical Announces Revenue and Profit Growth in 2025 and Dividend Plan

Chunli Medical to Release FY2025 Earnings on March 30 During-Market (BJT), Forecast Revenue CNY 1.146 B, EPS CNY 0.58

Spring Medical 2025 Annual Performance: Significant Growth in Revenue and Net Profit

Spring Medical's net profit increased by 117.72% in 2025

Chunli Medical released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 289.67 M, actual EPS CNY 0.2097

Chunli Medical released FY2025 earnings on February 27 During-Market (BJT), actual revenue CNY 1.046 B (forecast CNY 1.2 B), actual EPS CNY 0.71 (forecast CNY 0.58)

Spring Medical Announces Significant Increase in Net Profit for 2025

Spring Medical's shareholder resolutions not approved

Spring Medical uses idle fundraising proceeds to subscribe to Beijing Bank structured deposits

Huansan Securities Releases Report, Giving Spring Medical 'Buy' Rating

Chunli Medical Reports Strong Q3 2025 Profits, Enhanced Earnings Capacity

Spring Medical Obtains New Patent for Implant Prosthesis and Limb Sealing Device

Chunli Medical released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 756.09M, actual EPS CNY 0.4996

Chunli Medical released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 268.5 M, actual EPS CNY 0.1996

Chunli Medical to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

01858

688236

Beijing Chunlizhengda Medical Instruments Co., Ltd. has proposed a final cash dividend of RMB 1.5 per 10 shares for the financial year ending 31 December 2025, pending shareholder approval on 26 May 2026. The dividend for H shareholders will be paid in Hong Kong dollars, with details on the exchange rate to be announced later. The ex-dividend date is set for 28 May 2026, with a record date of 1 June 2026 and a payment date of 30 June 2026. The company also clarified withholding tax rules for various investor categories.

Tip Ranks

CHUNLI MEDICAL

Beijing Chunlizhengda Sets Final 2025 Dividend, Clarifies Withholding Tax Rules

01276

688428

600276

02196

600196

09969

Over half of listed Chinese drugmakers reported increased net profits for 2025, driven by innovative medicines and overseas business. Notable performers include Hengrui Pharmaceuticals, with a 22% profit rise to CNY7.7 billion, and InnoCare Pharma, achieving its first profit of CNY642 million. Fosun Pharmaceutical Group's net profit rose 22% to CNY3.4 billion, while Chunlizhengda Medical Instruments saw a 118% profit surge. The industry is focusing on innovative R&D and adapting to evolving consumer demands, with firms emphasizing integration of online and offline services.

Yicai

HENGRUI PHARMA

InnoCare Pharma

Hengrui Pharma

FOSUN PHARMA

INNOCARE

Over Half of Listed Chinese Drugmakers See 2025 Profit Grow Buoyed by Innovative Medicines, Overseas Business

Chunli Medical announced its full-year results for the year ended December last year, with a revenue of RMB 1.046 billion, an increase of 29.8% year-on-year. The net profit was RMB 273 million, an increase of 118.1% year-on-year; earnings per share were RMB 0.71. It plans to declare a final dividend of RMB 1.5 for every 10 shares, which is RMB 0.15 per share, compared to RMB 0.049 per share in the same period last year

AASTOCKS

"Performance" Chunli Medical's annual net profit is 273 million RMB, an increase of 118%, with earnings per share of 0.15 RMB

CHUNLI MEDICAL announced its performance preliminary report for the year 2025, achieving total operating revenue of 1.044 billion RMB (same below), an increase of 29.5% year-on-year. It recorded a net profit of 272 million RMB, a growth of 117.7%, with earnings per share of 0.71 RMB

"Performance" Chunli Medical's annual net profit is 272 million RMB, an increase of 117.7%

CHUNLI MEDICAL issued a profit warning, expecting a net profit attributable to the owners of the parent company to be between RMB 245 million and RMB 288 million for the fiscal year 2025, representing a growth of 96%-130.4% compared to the previous year. The reason is that the company's various product lines have gradually released growth potential after being included in centralized procurement, while the company steadily advances its international business layout, promoting continuous, stable, and healthy development of operating income both domestically and internationally

"Profit Alert" Chunli Medical forecasts annual net profit to increase by at least 96% to 245 million RMB

CHUNLI MEDICAL's stock price rose over 9% again, with a cumulative increase of nearly 25% after the earnings report. As of the time of writing, the stock price is HKD 20.44, with a trading volume of HKD 98.2915 million. The company's operating revenue for the first three quarters was RMB 756 million, a year-on-year increase of 48.75%; net profit was RMB 192 million, a year-on-year increase of 213.21%. The operating revenue for the third quarter was RMB 268 million, a year-on-year increase of 109.51%. Huatai Securities believes that overseas business has become an important source of revenue and expects it to continue to grow rapidly in the future, maintaining a "Buy" rating

Zhitong

Understanding the Market | Chunli Medical rises over 9% again, overseas business has become an important source of income, and third-quarter performance has grown rapidly year-on-year

CHUNLI MEDICAL recently released its performance for the first three quarters of 2025, with operating revenue of 756 million yuan, a year-on-year increase of 48.75%; net profit of 192 million yuan, a year-on-year increase of 213.21%. Affected by centralized procurement, the company's revenue in the third quarter of 2024 declined by 49.03% year-on-year, but with the end of inventory adjustments, performance has rebounded significantly. The stock price has risen by 122.13% this year

The impact of centralized procurement has dissipated, and the stock price of Chunli Medical has risen over 120% this year. Where will it head after three months of consolidation?

CHUNLI MEDICAL's stock price rose by more than 10%, with an increase of 10.66% as of the time of publication, reported at HKD 18.37, with a transaction volume of HKD 45.461 million. The company released its performance for the first three quarters of 2025, with operating revenue of 756 million yuan, a year-on-year increase of 48.75%; net profit attributable to the parent company of 192 million yuan, a year-on-year increase of 213.21%. In the third quarter, it achieved operating revenue of 268 million yuan, a year-on-year increase of 109.51%; net profit attributable to the parent company of 77.0619 million yuan, turning a profit. Huatai Securities pointed out that the company is actively expanding its international market, with rapid growth in overseas revenue, which has become an important source of income

Understanding the Market | Chunli Medical rose over 10%, turning a profit of 77.0619 million yuan in the third quarter as the company actively expands its international market business

According to the Zhitong Finance APP, Chunli Medical released its performance for the first three quarters of 2025, with the group achieving operating revenue of 756 million yuan, a year-on-year increase of 48.75%; the net profit attributable to shareholders of the listed company was 192 million yuan, a year-on-year increase of 213.21%. The basic earnings per share were 0.5 yuan

CHUNLI MEDICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 192 million yuan, a year-on-year increase of 213.21%

Chunli Medical(688236.SH)